hydroxychloroquine has been researched along with Vitiligo in 8 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment of vitiligo is often challenging to dermatologists." | 5.72 | Targets Exploration of Hydroxychloroquine for Pigmentation and Cell Protection Effect in Melanocytes: The Clue for Vitiligo Treatment. ( Chen, Y; Hu, Y; Luo, H; Song, X; Xie, B; Xu, J; Zhao, Y, 2022) |
| "Hydroxychloroquine (HCQ) is an effective immunomodulatory drug which is widely used in treatment of autoimmune disorders." | 5.72 | A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo. ( Darchini-Maragheh, E; Fathi-Najafi, S; Layegh, P; Meshkat, M; Rahsepar, S; Sazgarnia, S; Sepehr, V, 2022) |
| " Consequently, hydroxychloroquine and topical glucocorticoids therapy were initiated with reported improvement in pruritus, erythema, and scale." | 3.74 | Chronic cutaneous lupus erythematosus in vitiligo. ( Bossenbroek, NM; Johnson, H; Meehan, SA; Pomeranz, MK; Robles, M; Rosenman, K, 2008) |
| "Hydroxychloroquine (HCQ) is an effective immunomodulatory drug which is widely used in treatment of autoimmune disorders." | 1.72 | A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo. ( Darchini-Maragheh, E; Fathi-Najafi, S; Layegh, P; Meshkat, M; Rahsepar, S; Sazgarnia, S; Sepehr, V, 2022) |
| "Hydroxychloroquine (HCQ) is an effective immunosuppressant widely used in the treatment of autoimmune disorders." | 1.43 | Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes. ( Hu, WZ; Li, DG; Liu, W; Ma, HJ; Yang, QQ; Zhao, G, 2016) |
| "The hydroxychloroquine dose was tapered to 200 mg daily after 12 months, then to 100 mg daily after 18 months therapy." | 1.33 | Connective tissue panniculitis in a child with vitiligo and Hashimoto's thyroiditis. ( Mirza, B; Muir, J; Peake, J; Whitehead, K, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Xie, B | 1 |
| Chen, Y | 1 |
| Hu, Y | 1 |
| Zhao, Y | 1 |
| Luo, H | 1 |
| Xu, J | 1 |
| Song, X | 1 |
| Sazgarnia, S | 1 |
| Layegh, P | 1 |
| Darchini-Maragheh, E | 1 |
| Sepehr, V | 1 |
| Meshkat, M | 1 |
| Fathi-Najafi, S | 1 |
| Rahsepar, S | 1 |
| Niebel, D | 1 |
| Braegelmann, C | 1 |
| Bieber, T | 1 |
| Wenzel, J | 1 |
| Joo, K | 1 |
| Park, W | 1 |
| Kwon, SR | 1 |
| Lim, MJ | 1 |
| Jung, KH | 1 |
| Li, DG | 1 |
| Hu, WZ | 1 |
| Ma, HJ | 1 |
| Liu, W | 1 |
| Yang, QQ | 1 |
| Zhao, G | 1 |
| Johnson, H | 1 |
| Bossenbroek, NM | 1 |
| Rosenman, K | 1 |
| Meehan, SA | 1 |
| Robles, M | 1 |
| Pomeranz, MK | 1 |
| Mirza, B | 1 |
| Muir, J | 1 |
| Peake, J | 1 |
| Whitehead, K | 1 |
| Walsh, DS | 1 |
| Farley, MF | 1 |
| Beard, JS | 1 |
| Sau, P | 1 |
| Tesar, J | 1 |
| James, WD | 1 |
8 other studies available for hydroxychloroquine and Vitiligo
| Article | Year |
|---|---|
Targets Exploration of Hydroxychloroquine for Pigmentation and Cell Protection Effect in Melanocytes: The Clue for Vitiligo Treatment.
Topics: Carrier Proteins; Cytoprotection; Humans; Hydroxychloroquine; Melanocytes; Molecular Docking Simulat | 2022 |
A Preliminary Study on the Therapeutic Effects of Hydroxychloroquine on Generalized Vitiligo.
Topics: Adolescent; Adult; Autoimmune Diseases; Female; Humans; Hydroxychloroquine; Male; Treatment Outcome; | 2022 |
Vitiligo-like depigmentation subsequent to subacute cutaneous lupus erythematosus and hydroxychloroquine treatment.
Topics: Humans; Hydroxychloroquine; Hypopigmentation; Lupus Erythematosus, Cutaneous; Vitiligo | 2020 |
Improvement of vitiligo in a patient with rheumatoid arthritis after hydroxychloroquine treatment.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Female; Humans; Hydroxychloroquine; Remission In | 2015 |
Hydroxychloroquine protects melanocytes from autoantibody-induced injury by reducing the binding of antigen-antibody complexes.
Topics: Adolescent; Adult; Antibody-Dependent Cell Cytotoxicity; Antigen-Antibody Complex; Autoantibodies; A | 2016 |
Chronic cutaneous lupus erythematosus in vitiligo.
Topics: Autoimmunity; Carcinoma, Squamous Cell; Clobetasol; Diabetes Complications; Diagnostic Errors; Drug | 2008 |
Connective tissue panniculitis in a child with vitiligo and Hashimoto's thyroiditis.
Topics: Biopsy, Needle; Child; Connective Tissue; Drug Therapy, Combination; Female; Follow-Up Studies; Huma | 2006 |
Systemic lupus erythematosus: nephritis, dilated cardiomyopathy, and extensive cutaneous depigmentation responsive to hydroxychloroquine.
Topics: Adult; Cardiomyopathy, Dilated; Humans; Hydroxychloroquine; Hypopigmentation; Lupus Erythematosus, S | 1995 |